Zinger Key Points The Food and Drug Administration has granted the company’s LSD treatment for generalized anxiety disorder a “breakthrough therapy” status. A single oral administration of ...

Mind Medicine Inc.’ stock surged 6.5% Thursday, after the company said a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically ...

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD ...

The US Food and Drug Administration (FDA) has granted breakthrough designation to an LSD-based treatment for generalized anxiety disorder (GAD) based on promising topline data from a phase 2b ...